Advanced glycation end-products: A review

Diabetologia

Volumn 44, Issue 2, 2001, Pages 129-146

  Singh, R ^a   Barden, A ^a   Mori, T ^a   Beilin, L ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Advanced glycated end products; Aminoguanidine; Carbonyl stress; Diabetes mellitus; Microvascular disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE;

CHEMICAL STRUCTURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HUMAN; MICROANGIOPATHY; PRIORITY JOURNAL; REVIEW;

AGING; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FOOD; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PLANTS, TOXIC; RECEPTORS, IMMUNOLOGIC; TOBACCO;

EID: 0035135246     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051591     Document Type: Review

References (155)

1. The effect of intensive diabetes treatment on the development and progression of long term complications in insulin dependent diabetes mellitus: The diabetes control and complications trial
2. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type II diabetes: (UKPDS 33)
3. Diabetes and coronary heart disease- from prevention to intervention: Part 1
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38)
5. The maillard or browning reaction in diabetes
6. Advanced glycation end-products in children and adolescents with diabetes mellitus: Relation to glycaemic control and early microvascular complications
7. Role of glycation in aging
8. Advanced glycation: Chemistry, biology and implications for diabetes and aging
9. AGE: A nephrologist's perspective
10. Reduction of plasma apolipoprotein B by effective removal of circulating glycation derivatives in uraemia
11. Advanced glycation end products in diabetic nephropathy
12. AGE and their interaction with AGE-receptors in vascular disease and diabetes. I. The AGE concept
13. Generation of oxygen species from AGE during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damage
14. AGE's in aging and alzheimers disease
15. Quantitative analysis of cross-links pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders
16. End stage renal disease and diabetes catalyse the formation of a pentose-derived cross-link form aging human collagen
17. AGE and cigarette smoking
18. Nutritional and toxocological aspects of the maillard browning reaction in foods
19. Lipid and lipoprotein modification by AGE's: Role in atherosclerosis
20. AGE's and atherosclerosis
21. Pharmacological reversal of AGE-mediated protein cross-linking
22. Pimagedine lowers total urinary protein and slows progression of overt diabetic nephropathy in patients with type I diabetes
23. Pimagedine reduces progression of retinopathy and lowers lipid concentrations in patients with type I diabetes
24. Pimagedine safety profile in patients with Type I diabetes
25. Diabetic late complications: Will aldose reductase inhibitors or inhibitors of advanced glysosylation end-product formation hold promise?
26. Recent progress in advanced glycation and diabetic vascular disease: Role of AGE receptors
27. Glycated proteins in diabetes
28. Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus
29. Advanced glycation end products, oxidant stress and vascular lesions
30. Oxidation conspires with glycation to generate noxious advanced glycation end-products in renal failure
31. Characterisation of a novel age-compound derived from lysine and 3-deoxyglucasone
32. New biomarkers of maillard reaction damage to proteins
33. Role of oxidative stress in diabetic complications a new perspective on an old paradigm
34. Re-investigation of lipid peroxidation of linoleic acid
35. Experimental diabetic neuropathy: An update
36. Normalising mitochondrial superoxide production blocks three pathways of hyperglycaemia induced damage
37. Pharmacology of methylglyoxal
38. Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes
39. Formation of glyoxal, methylglyoxal and 3-DG in the glycation of proteins
40. Induction of apoptic cell death by methylglyoxal and 3-deoxyglucasone in macrophage derived cell lines
41. Alteration in non-enzymatic biochemistry in uraemia: Origin and significance of "carbonyl stress" in long term uraemic complications
42. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification in protein in diabetic glomerular lesions
43. Role of the maillard reaction in aging of tissue proteins
44. Accumulation of albumin-linked and free-from pentosidine in the circulation of uraemic patients with end-stage renal failure: Renal implications in the pathology of pentosidine
45. Glycation, glyoxidation and cross-linking of collagen by glucose: Kinetics, mechanisms and inhibition of late stages of the maillard reaction
46. Membrane proteins of human erythrocytes are modified by advanced glycation end-products during aging in the circulation
47. The advanced glycated end-product N-(carboxymethyl) lysine, is a product of both lipid peroxidation and glyoxidation reactions
48. Lipoxidation products as biomarkers of oxidative damage to protein during lipid peroxidation reactions
49. Glycation of immunoglobulins and serum proteins
50. Tobacco smoke is a source of toxic reactive glycation products
51. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
52. The pathogenesis of atherosclerosis: A perspective for the 1990 s
53. The mechanism of collagen cross-linking in diabetes: A puzzle nearing resolution
54. The effect of advanced glycated end-product formation upon cell-matrix interaction
55. The role of glycation cross-links in diabetic vascular stiffening
56. Advanced glycated end-products in diabetic tissues using monoclonal antibody to pyrraline
57. Atherogenesis and advanced glycation: Promotion, progression and prevention
58. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGE
59. Diabetes
60. Molecular mechanisms of diabetic angiopathy clues for innovative theraputic interventions
61. Activation for the receptor for AGE triggers a p21 ras dependent mitogen activated protein kinase pathway regulated by oxidant stress
62. RAGE a novel receptor for AGE's
63. Enhanced cellular oxidant stress by the interaction of AGE's with their receptors/binding proteins
64. Cellular receptors for AGE's: Implication for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
65. Advanced glycation end-products induced activation of NF-κB is suppressed by α-lipoic acid in cultured endothelial cells
66. High molecular weight hyaluronic acid inhibits advanced glycation end-product induced NF-kappaB activation and cytokine expression
67. The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine in proteins: A mechanism for producing advanced glycation end-products at sites of inflammation
68. Activation of receptor for advanced glycation end-products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
69. Receptor for advanced glycated end-products (RAGE)-mediated neurite outgrowth and activation of NF-kappa B require the cytoplasmic domain of the receptor but different downstream signalling pathways
70. Regulation of cell migration by amphoterin
71. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
72. Glycaemia and the regulation of endothelial adhesion molecules
73. Cellular molecular abnormalities in the vascular endothelium of diabetes mellitus
74. Non-enzymatic glycosylation and the chronic complications of diabetes: An overview
75. Advanced glycosylation in diabetes and aging
76. The role of advanced glycation end products in the pathogenesis of atherosclerosis
77. Insulin enhances macrophage scavenger receptor mediated endocytic uptake of advanced glycated end products
78. Advanced glycation end products in diabetic nephropathy
79. AGE's are eliminated by scavenger receptor mediated endocytosis of hepatic sinusoidal kupffer cells and endothelial cells
80. Cardiovascular risk continuum: Implication of insulin resistance and diabetes
81. Characterisation of antibody to advanced glycated end-products on protein
82. Advanced glycosylated end-products and hyperglycaemia in the pathogenesis of diabetic complications
83. Increased serum concentrations of advanced glycated end-products (AGE) in children and adolescents with IDDM
84. Increased accumulation of the glyoxidation product N (epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging
85. Determination of urinary and serum pentosidine and its application to older patients
86. Relation between pentosidine concentrations in serum and urine and activity of rheumatoid arthritis
87. Immunological quantification of AGE's in serum of patients on haemodialysis or peritoneal dialysis
88. Quantification of the cross-link pentosidine in serum from normal and uremic subjects
89. Radioreceptor assay for advanced glycation end-products
90. Chromatographic evidence for pyrraline formation during protein glycation in vitro and in vivo
91. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma
92. Elevated AGE-modified Apo B in sera of euglycaemic, normolipidaemic patients with atherosclerosis: Relation to tissue AGE
93. Standardising the immunological measurement of advanced glycation end products using normal human serum
94. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competative ELISA
95. Advanced glycation end-products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury
96. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissue of patients on maintenance dialysis and kidney transplantation
97. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the maillard reaction
98. Amelioration of vascular dysfunction in diabetic rats by an oral protein kinase C beta inhibitor
99. Preventative effect of long term aldose reductase inhibitor (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat
100. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycated end-products
101. Hyperglycaemia: The bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications
102. AGE induce oxidative stress and activate protein kinase C-beta (II) in neonatal mesangial cells
103. Biochemical markers of diabetic microangiopathy. Past, present and future
104. In vivo platelet activation in diabetes mellitus
105. Expression of receptors for AGE's in peripheral occlusive vascular disease
106. Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity
107. Pathogenic effects of advanced glycosylation: Biochemical, biological and chemical implications for diabetes and aging
108. Advanced glycated end-products (AGE) co-localise with AGE receptors in the retinal vasculature of diabetic and AGE infused rats
109. Advanced glycated end-product driven angiogenesis in vitro
110. The relation between accumulation of advanced glycated end-products and expression of vascular endothelial growth factor in human diabetic retinas
111. Differential accumulation of advanced glycated end-products in the course of diabetic retinopathy
112. Negative consequences of glycation
113. The contribution of glycation to cataract formation in diabetes
114. Fructose mediated damage to lens alpha-crystallin: Prevention by pyruvate
115. Cytotoxicity of advanced glycation end-products is mediated by oxidative stress
116. Non-enzymatic glycosylation of peripheral nerve protein in diabetes
117. Functional and structural abnormalities in the nerves of Type I diabetic baboons: Aminoguanidine does not improve nerve function
118. Non-enzymatic glycosylation of laminin and the laminin peptide CI-KVAVS inhibits neurite outgrowth
119. Non-enzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: A model for intracellular glycosylation in diabetes
120. Localisation in human diabetic peripheral nerve of N epsilon-carboxymethyl-lysine protein adducts, an advanced glycated end-product
121. Selective vulnerability of spinal motor neurones to reactive dicarbonyl compounds, intermediate products of glycation, in vitro: Implication of inefficient glutathione system in spinal motor neurones
122. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end-product inhibitor OPB-9195
123. Pathogenic role of AGE's in diabetic nephropathy
124. Hyperglycaemia and diabetic kidney disease. The case for transforming growth factor beta as a key mediator
125. Human mesangial cells and periheral blood mononuclear cells produce vascular permeability factor
126. Advanced glycated end-products in tissue and the biochemical basis of diabetic complications
127. Immunocytochemical detection of AGE's in rat renal tissue as a function of age and diabetes
128. Implication of carbonyl stress in long term uraemic complications
129. Advanced glycation of β2 microglobulin in the pathogenesis of bone lesions in dialysis associated amyloidosis
130. Advanced glycation end-products enhance osteoclast-induced bone resorption in cultured mouse infractionated bone cells and in rats implanted subcutaneously with devitalised bone particles
131. "Carbonyl stress" and dialysis related amyloidosis
132. Clearance of pentosidine, an advanced glycated end-product, by different modalities of renal replacement therapy
133. Immunocytochemical localisation of AGE's in coronary atheroma and cardiac tissue in diabetes
134. Oxidation of LDL leads to particle aggregation and altered macrophage recognition
135. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glyctaed end-products
136. Glycation of VLDL from rat plasma impairs its catabolism
137. Binding of long term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells
138. Glycation impairs high density lipoprotein function
139. Glycation amplifies lipoprotein (a)-induced alteration in the generation of fibrinolytic regulators from human vascular endothelial cells
140. Amadorins: Novel post-amadori inhibitors of advanced glycation end-products
141. Role of the maillard reaction in diabetes mellitus and diseases of aging
142. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant induced apoptosis
143. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration
144. Biological effects of aminoguanidine: An update
145. Free radicals produced during the oxidation of hydrazines by hypochlorous acid
146. Antineutrophil cytoplasmic antibodies: A still growing class of auto-antibodies in inflammatory disorders
147. Mechanism of drug induced lupus
148. Advanced glycation end-product concentrations in sub-totally nephrectomised rats: Beneficial effects of angiotensin II receptor I antagonist losartan
149. Antioxodant treatment of experimental diabetic retinopathy in rats with nicarnitine
150. An agent cleaving glucose-derived protein cross-linking in vitro and in vivo
151. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine
152. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycated end-product accumulation
153. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes
154. Role of amadori modified non-enzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy